NCT00425932View on ClinicalTrials.gov

Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2012

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Rituximab

At Week 24 or any time up to Week 48 if the Patient DAS 28 \> 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.

Trial Locations (6)

33021

Drs. Charles Kahn and Wayne Riskin, Hollywood

33180

Arhtritis & Rheumatic Disease Specialties, Miami

33324

Guillermo Valenzuela MD, Fort Lauderdale

67220

Arthritis and Rheumatology Clinics of Kansas, Wichita

73103

McBride Clinic Orthopedic Center, Oklahoma City

73104

Oklahoma Medical Research Foundation, Oklahoma City

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Oklahoma Medical Research Foundation

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Gaylis, Norman B., M.D.

INDIV